Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21560172 | 0.91 | MAPT (0.57) | MAPTLMNATP53TRPM8ALDH1A1 | |
| SCHEMBL3374076 | 0.89 | MEN1 (0.57) | MAPTLMNATP53KDM4EALDH1A1 | |
| SCHEMBL31578670 | 0.87 | ALDH1A1 (0.60) | MAPTLMNATP53KDM4EALDH1A1 | |
| SCHEMBL8847666 | 0.87 | MAPT (0.53) | MAPTLMNATP53KDM4ETRPM8 | |
| SCHEMBL2073208 | 0.86 | MAPT (0.65) | MAPTLMNATP53KDM4EALDH1A1 | |
| SCHEMBL3371234 | 0.86 | RAB9A (0.54) | MAPTLMNATP53KDM4ETRPM8 | |
| SCHEMBL11157975 | 0.86 | MEN1 (0.62) | MAPTLMNAKDM4EALDH1A1MEN1 | |
| SCHEMBL4907597 | 0.86 | LMNA (0.67) | MAPTLMNATP53KDM4ETRPM8 | |
| SCHEMBL20241864 | 0.86 | SHMT1 (0.64) | MAPTLMNATP53KDM4EALDH1A1 | |
| SCHEMBL11164179 | 0.86 | MEN1 (0.60) | MAPTLMNATP53KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091451-B2 | SHMT inhibitors and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2015172196-A1 | HETEROCYCLIC COMPOUNDS AND USE OF SAME | MONASH UNIVERSITY (AU) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015172196-A1 | HETEROCYCLIC COMPOUNDS AND USE OF SAME | MONASH UNIVERSITY (AU) | 2015-11-19 | — | — | WO | disclosed |
| CN-1633434-A | Imidazo [1, 2-a ] pyridine derivatives | DAIICHI SEIYAKU CO (JP) | 2005-06-29 | — | — | CN | disclosed |
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| EP-1479681-A1 | IMIDAZO(1,2-a)PYRIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-20030171588-A1 | 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof | LION BIOSCIENCE AG (DE) | 2003-09-11 | — | — | US | disclosed |
| US-4683227-A | CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
| EP-0211526-A2 | Cephalosporins, their preparation and formulations | ELI LILLY AND COMPANY (US) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171588-A1 | 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof | BRD4, BICRA, HDAC6 | MAPT 1410/4885LMNA 3593/4885TP53 4615/4885 |
| US-11091451-B2 | SHMT inhibitors and uses thereof | SHMT1, SHMT2, BHMT | MAPT 1852/4885LMNA 4283/4885TP53 506/4885 |
| US-20190345119-A1 | SHMT INHIBITORS AND USES THEREOF | SHMT1, SHMT2, BHMT | MAPT 1852/4885LMNA 4283/4885TP53 506/4885 |
| US-20050113397-A1 | Imidazo[1,2-a]pyridine derivative | MANBA, MAN2B1, ERG28 | MAPT 1694/4885LMNA 3993/4885TP53 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.